23 Ha'Taas Street
About Cellect BiotechnologyCellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni and Dr. Nadir Ashkenazy with a vision of enabling regenerative medicine to become reality. YEAR FOUNDED:
Founders: Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Ashkenazy
Founder and CEO: Shai Yarkoni
CFO: Eyal Leibovitz
CDO: Yaron Pereg
40 articles with Cellect Biotechnology
Recent Clinical Achievements Demonstrate Continued Momentum in the U.S. and Israel
Cellect Biotechnology Announces Positive Outcome From Safety Review Committee; Successfully Transplants 9th Clinical Trial Patient
Solid progress as Washington University's Scientific Review Committee Approved the Company's First U.S. Study
Collaboration Achieves First Significant Milestone with Successful Execution of Technology Transfer
Cellect Biotechnology Ltd., a developer of innovative technology which enables the functional selection of stem cells, reported financial and operating results for the first quarter ended March 31, 2019 and provided a corporate update.
Further validating its ApoGraft™ technology, Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced positive mid-study data from the Company's Phase I/II study of its ApoGraft™ technology
Cellect Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress
Milestone Execution Positions the Company for Expedited Progress in 2019
Cellect Announces Positive Results From Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells
Results and Validation of ApoGraft technology from a variety of sources could lead to a more cost-effective solution for the cell therapy industry.
Cellect Begins Collaboration with Washington University in Preparation for First U.S. Clinical Trial Using Cellect's ApoGraft™ for Bone Marrow Transplantations
The Collaboration will be led by Renowned Cell and Gene Therapy Experts Dr. John DiPersio and Dr. Mark Schroeder with Advisory support to Cellect by Prof. Negrin of Stanford and Dr. Cutler of Harvard Medical School
Completion of Manufacturing of Clinical Grade FasL Enables Cellect to Expedite U.S. Clinical Programs into Multiple Studies
Supports Collaborations with Cell and Gene Therapy Companies
Cellect Biotechnology Reports Clinical and Regulatory Milestone Targets Through the Second Quarter of 2020
Recent FDA Hiring Decision Highlights Growing Importance of Cell and Gene Therapy Companies
Further to the Announcement of the Agreement Signed With the South Korean Cell2in: KORIL Approves Cellect's Grant Application
Cellect Biotechnology (Nasdaq: APOP), a developer of a novel stem cell production technology, announced that KORIL-RDF, has approved Cellect's grant application, submitted with Cell2in, a Korean cell therapy company with whom a collaboration agreement was signed recently.
Cellect Biotechnology Ltd. today provided a corporate update and announced financial results for the third quarter ended September 30, 2018.
Following US, EU, Russia and South Korean approval, Cellect Technology Patent has now also been approved in Japan and Australia
Cellect Biotechnology Ltd. announced today its CEO Dr. Shai Yarkoni will present at the 24th Annual Bio Europe Conference.
Positive Results of Orthopedic Treatment With the Use of ApoGraft™ Enriched Stem Cells Derived From Fat Tissues
Study shows significant improvement in orthopedic healing process
One-month assessment of half of the planned patients in the ApoGraft™ study show complete engraftment and zero related adverse events
In Korea, Cellect recently signed collaboration agreement with Cell2in to improve stem cell selection and expansion
Aim is to combine the benefits of mutual technologies to enable higher quality cells at a lower cost
Cellect Biotechnology Ltd. provided a corporate update and announced financial results for the second quarter ended June 30, 2018.
Covers ApoGraft's uses, methods and devices in stem cell selection for conditions including GvHD